Skip to content

L · 0JAV.L · BIOTECHNOLOGY

Insmed Incorporated (0JAV.L) intrinsic value and stock valuation

$143.51as of 2026-11-21 · Mkt cap 23.2B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Insmed Incorporated DCF and intrinsic value

InvestorsCraft values 0JAV.L with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from 0JAV.L’s statements →

Insmed Incorporated Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Bridgewater, NJ 08807 insmed.com

How the business is doing

Fiscal 2012–2025, USD

Revenue
$606.4M+29.8% 5y CAGRd
20122025
Net income
-$-1.28B
20122025
Free cash flow
-$-997.58M
20122025
Total equity
$739M+21.8% 5y CAGRd
20122025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2012–2025, USD
20252024202320222021
Revenue$606.4M$363.7M$305.2M$245.4M$188.5M
Operating income-$-994.78M-$-786.57M-$-709.63M-$-478.12M-$-367.16M
Net income-$-1.28B-$-913.77M-$-749.57M-$-481.53M-$-434.65M
EPSd-$-6.42M-$-5.57M-$-5.34M-$-3.91M-$-3.88M
Operating cash flow-$-935.01M-$-683.88M-$-536.25M-$-400.44M-$-363.3M
Capital expenditure-$-62.56M-$-21.92M-$-13.29M-$-9.88M-$-7.29M
Free cash flow-$-997.58M-$-705.8M-$-549.53M-$-410.32M-$-370.59M
Total assets$2.26B$2.03B$1.33B$1.66B$1.24B
Total debt$768.2M$1.33B$1.37B$1.34B$612.3M
Net debt$257.7M$771.4M$890.6M$262.1M-$-104.51M
Total equity$739M$285.4M-$-331.92M$88M$410.5M
Cash and short-term investments$1.43B$1.43B$780.5M$1.15B$716.8M
Income statement
20252024202320222021
Revenue$606.4M$363.7M$305.2M$245.4M$188.5M
Cost of revenue$128.9M$90.8M$65.6M$60.2M$49.2M
Gross profit$477.5M$272.9M$239.6M$185.2M$139.3M
Research and development expenses$771.1M$598.4M$575.9M$397.5M$272.7M
Selling, general and administrative expenses$701.2M$461.1M$344.5M$265.8M$233.7M
Other expenses$0.00$0.00$28.9M$0.00$0.00
Operating expenses$1.47B$1.06B$949.3M$663.3M$506.4M
Cost and expenses$1.6B$1.15B$1.01B$723.5M$555.6M
Interest income$60.7M$53.3M$42.1M$11.1M$170K
Interest expense$83.8M$84.9M$81.7M$26.5M$40.5M
Depreciation and amortization$16.5M$11M$8.44M$24.3M$27.9M
Ebitda-$-978.33M-$-814.14M-$-672.49M-$-429.44M-$-368.09M
Operating income-$-994.78M-$-786.57M-$-709.63M-$-478.12M-$-367.16M
Total other income/expenses, net-$-276.97M-$-123.5M-$-37.39M-$-2.03M-$-69.25M
Income before tax-$-1.27B-$-910.07M-$-747.01M-$-480.15M-$-436.41M
Income tax expense$5.03M$3.71M$2.56M$1.38M-$-1.76M
Net income-$-1.28B-$-913.77M-$-749.57M-$-481.53M-$-434.65M
Weighted average shares outstanding$199M$164M$140.4M$123M$112.1M
Weighted average diluted shares outstanding$199M$164M$140.4M$123M$112.1M
Balance sheet
20252024202320222021
Cash and short-term investments$1.43B$1.43B$780.5M$1.15B$716.8M
Net receivables$140.9M$52M$41.2M$29.7M$24.4M
Inventory$132.1M$98.6M$83.3M$69.9M$67M
Total current assets$1.79B$1.62B$929.1M$1.27B$837M
Property, plant and equipment, net$139.2M$115.6M$104.4M$102.1M$95.5M
Goodwill and intangible assets$233.8M$194.8M$199.8M$167.3M$167.5M
Long-term investments$0.00$0.00$0.00$0.00$50M
Total non-current assets$470.4M$403.6M$400.8M$383.1M$406.5M
Total assets$2.26B$2.03B$1.33B$1.66B$1.24B
Accounts payable$79.9M$73M$65.4M$50.5M$35.8M
Short-term debt$19.3M$28.8M$24.6M$18.4M$20.3M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$468.9M$297.5M$225.6M$190.2M$135.2M
Long-term debt$748.9M$1.3B$1.35B$1.32B$602.1M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$1.06B$1.44B$1.44B$1.38B$697.9M
Capital lease obligations$32.9M$45.5M$48.7M$52.6M$45.7M
Total liabilities$1.53B$1.74B$1.66B$1.57B$833M
Common stock$2.14M$1.79M$1.48M$1.36M$1.19M
Retained earnings-$-5.64B-$-4.36B-$-3.45B-$-2.7B-$-2.27B
Accumulated other comprehensive income (loss)$1.46M-$-2.29M-$-740K$760K$970K
Total equity$739M$285.4M-$-331.92M$88M$410.5M
Total investments$919.6M$878.8M$298.1M$74.2M$50M
Total debt$768.2M$1.33B$1.37B$1.34B$612.3M
Net debt$257.7M$771.4M$890.6M$262.1M-$-104.51M
Cash flow statement
20252024202320222021
Net income-$-1.28B-$-913.77M-$-749.57M-$-481.53M-$-434.65M
Depreciation and amortization$16.5M$11M$10.6M$24.3M$46.3M
Stock-based compensation$0.00$0.00$74.8M$57.7M$46M
Change in working capital-$-80.3M-$-3.18M-$-54.37M$6.58M-$-58.58M
Accounts receivable-$-88.31M-$-12.93M-$-11.96M-$-6.42M-$-8.12M
Inventory-$-31.52M-$-17.04M-$-13.61M-$-1.71M-$-17.46M
Accounts payable$100.1M$44.6M$15.2M$50M-$-7.58M
Net cash provided by operating activities-$-935.01M-$-683.88M-$-536.25M-$-400.44M-$-363.3M
Investments in property, plant and equipment-$-62.56M-$-21.92M-$-13.29M-$-9.88M-$-7.29M
Acquisitions, net$0.00$0.00$3.42M$24.7M-$-6.7M
Net cash used for investing activities-$-64.58M-$-583.17M-$-223.6M-$-34.58M-$-64.28M
Common stock issued$959M$1.2B$170.9M$311.7M$291.9M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$954.1M$1.34B$168.4M$793.3M$612.6M
Net change in cash-$-44.59M$72.7M-$-591.66M$357.3M$184M
Cash at end of period$510.4M$555M$482.4M$1.07B$716.8M
Operating cash flow-$-935.01M-$-683.88M-$-536.25M-$-400.44M-$-363.3M
Capital expenditure-$-62.56M-$-21.92M-$-13.29M-$-9.88M-$-7.29M
Free cash flow-$-997.58M-$-705.8M-$-549.53M-$-410.32M-$-370.59M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Insmed Incorporated

        Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.

        CEO
        William H. Lewis
        Employees
        1.27K
        Beta
        0.89

        Explore

        Frequently asked questions

        What is the intrinsic value of Insmed Incorporated (0JAV.L)?

        InvestorsCraft does not currently publish an intrinsic value for 0JAV.L. How the IC value is calculated.

        Is 0JAV.L undervalued?

        InvestorsCraft does not publish an undervaluation signal for 0JAV.L at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.